Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
My American Story
Roads, Travel and Traffic
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Jobs
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
My American Story
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Jobs
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Viking Therapeutics, Inc. - Common Stock
(NQ:
VKTX
)
39.51
-0.03 (-0.08%)
Streaming Delayed Price
Updated: 3:45 PM EDT, Jun 30, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Viking Therapeutics, Inc. - Common Stock
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
32
33
Next >
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
July 23, 2025
Via
Benzinga
Viking Therapeutics Inc (NASDAQ:VKTX) Posts Wider Q2 2025 Loss, Shares Drop in After-Hours Trading
↗
July 23, 2025
Viking Therapeutics reports wider Q2 2025 loss, missing EPS estimates, causing a 5.7% after-hours dip. Focus remains on clinical pipeline progress amid revenue challenges.
Via
Chartmill
Earnings Scheduled For July 23, 2025
↗
July 23, 2025
Via
Benzinga
A Look Ahead: Viking Therapeutics's Earnings Forecast
↗
July 22, 2025
Via
Benzinga
Better Growth Buy: Eli Lilly vs. Viking Therapeutics
↗
July 22, 2025
Via
The Motley Fool
3 Monster Stocks in the Making to Buy Right Now
↗
July 21, 2025
Via
The Motley Fool
These 2 Stocks Could More Than Double Your Money, According to Wall Street. Is It Time to Buy?
↗
July 20, 2025
Via
The Motley Fool
After Falling 68%, Where Will This Weight-Loss Drug Stock Be in 2 Years? History Shows Massive Gains Ahead.
↗
July 19, 2025
Yet another biopharma name has been run through a familiar trading cycle that often ends on a bullish note.
Via
The Motley Fool
Topics
Intellectual Property
The Best Stocks to Invest $1,000 In Right Now
↗
July 15, 2025
Via
The Motley Fool
Topics
Artificial Intelligence
Economy
Better Growth Buy: Eli Lilly vs. Viking Therapeutics
↗
July 07, 2025
Via
The Motley Fool
Why I Think Viking Therapeutics Is an Asymmetric Growth Opportunity
↗
July 04, 2025
Via
The Motley Fool
Topics
Artificial Intelligence
2 Beaten-Down Stocks With Massive Upside Potential
↗
July 03, 2025
Via
The Motley Fool
10 Incredible Growth Stocks Poised for Long-Term Gains
↗
July 02, 2025
Via
The Motley Fool
Topics
Artificial Intelligence
Got $200? 2 Biotech Stocks to Buy and Hold Forever
↗
July 01, 2025
Via
The Motley Fool
Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment?
↗
June 30, 2025
The company announced a new drug that uses the same mechanism as Eli Lilly's retatrutide.
Via
Investor's Business Daily
3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking
June 29, 2025
Timing matters with biotech stocks; these three companies offer distinct risk-reward profiles but have upcoming catalysts that could redefine their value
Via
MarketBeat
Topics
Artificial Intelligence
Economy
Why This Weight Loss Drug Company's Stock Surged Today
↗
June 26, 2025
Via
The Motley Fool
3 Growth Stocks I'm Loading Up On
↗
June 26, 2025
Via
The Motley Fool
Topics
Artificial Intelligence
Government
Why Viking Therapeutics, 67% Off Its Recent Highs, Could Still Have An Edge In Obesity
↗
June 25, 2025
The company just initiated two Phase 3 studies of its weekly under-the-skin shot to stoke weight loss.
Via
Investor's Business Daily
What's Going On With Viking Therapeutics Stock On Wednesday?
↗
June 25, 2025
Viking Therapeutics begins Phase 3 trials for VK2735, testing weekly injections in over 5,000 adults with obesity or type 2 diabetes over 78 weeks.
Via
Benzinga
My 5 Favorite Dirt Cheap Stocks to Buy Right Now
↗
June 24, 2025
Via
The Motley Fool
Topics
Artificial Intelligence
Economy
World Trade
Amgen Expands Development Plans For Highly Anticipated Obesity Drug
↗
June 23, 2025
Amgen is expanding its plans for weight-loss drug, MariTide, with a trio of upcoming Phase 3 studies.
Via
Investor's Business Daily
2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts
↗
June 21, 2025
Via
The Motley Fool
Missed Out on Eli Lilly's 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside.
↗
June 18, 2025
Via
The Motley Fool
Are These 2 High-Flying Growth Stocks Still Worth Buying After Recent Pullbacks?
↗
June 16, 2025
Via
The Motley Fool
Topics
Government
10 Health Care Stocks Whale Activity In Today's Session
↗
June 10, 2025
Via
Benzinga
1 Stock Down 34% This Year to Buy and Hold
↗
June 08, 2025
Via
The Motley Fool
Could Viking Therapeutics Become the Next Eli Lilly?
↗
June 02, 2025
Via
The Motley Fool
3 Best Growth Stocks to Buy in June
↗
June 02, 2025
Via
The Motley Fool
Topics
Artificial Intelligence
Economy
Government
Better Weight Loss Stock: Amgen or Viking Therapeutics?
↗
May 22, 2025
Via
The Motley Fool
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
32
33
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today